Search research articles
Contact Us
Filters
Showing results (71-80 of 154) with videos related to
Page
of 16
Sort By:
Journal of Medical Economics
|
October 12, 2013
Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey
Marc Evans, Henrik Holm Jensen, Mette Bøgelund, et al.
Endocrinology, Diabetes & Metabolism
|
July 19, 2021
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
Lyndon Marc Evans, Linda Mellbin, Pierre Johansen, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 10, 2003
Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?
Kerry Starkey, Armin Heufelder, Glynn Baker, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 2, 2013
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes
Craig J Currie, Chris D Poole, Marc Evans, et al.
Advances in Therapy
|
April 20, 2020
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
Marc Evans, Robert G J Moes, Katrine S Pedersen, et al.
Diabetes, Obesity & Metabolism
|
October 17, 2022
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11
Marc Evans, Barrie Chubb, Samuel J P Malkin, et al.
Pharmacoeconomics
|
June 28, 2006
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies
Adrian Bagust, Marc Evans, Sophie Beale, et al.
Journal of the American Heart Association
|
November 13, 2019
Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
Cecilia Linde, Ameet Bakhai, Hans Furuland, et al.
BMJ (Clinical Research Ed.)
|
July 8, 2025
NHS 10 year plan: Can using AI offer a solution to the NHS' problems?
W David Strain, Joshua Cronin-Lampe, Marc Evans, et al.
Advances in Therapy
|
February 10, 2024
Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor
Marc Evans, Mansoor Husain, Ayush Srivastava, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 154) with videos related to
Sort By:
Page
of 16
Journal of Medical Economics
|
October 12, 2013
Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey
Marc Evans, Henrik Holm Jensen, Mette Bøgelund, et al.
Endocrinology, Diabetes & Metabolism
|
July 19, 2021
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
Lyndon Marc Evans, Linda Mellbin, Pierre Johansen, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 10, 2003
Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?
Kerry Starkey, Armin Heufelder, Glynn Baker, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 2, 2013
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes
Craig J Currie, Chris D Poole, Marc Evans, et al.
Advances in Therapy
|
April 20, 2020
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
Marc Evans, Robert G J Moes, Katrine S Pedersen, et al.
Diabetes, Obesity & Metabolism
|
October 17, 2022
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11
Marc Evans, Barrie Chubb, Samuel J P Malkin, et al.
Pharmacoeconomics
|
June 28, 2006
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies
Adrian Bagust, Marc Evans, Sophie Beale, et al.
Journal of the American Heart Association
|
November 13, 2019
Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
Cecilia Linde, Ameet Bakhai, Hans Furuland, et al.
BMJ (Clinical Research Ed.)
|
July 8, 2025
NHS 10 year plan: Can using AI offer a solution to the NHS' problems?
W David Strain, Joshua Cronin-Lampe, Marc Evans, et al.
Advances in Therapy
|
February 10, 2024
Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor
Marc Evans, Mansoor Husain, Ayush Srivastava, et al.
Page
of 16